Prostate Specific Antigen News and Research

RSS

New urine test could avoid unnecessary prostate cancer biopsies

A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients.

11 Feb 2021

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

11 Feb 2021

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer

Researchers from Hong Kong Baptist University and the Faculty of Medicine at The Chinese University of Hong Kong have jointly developed the Spermine Risk Score which, coupled with the use of a urine test, provides a non-invasive and more reliable method for the diagnosis of prostate cancer.

8 Feb 2021

New technique can rapidly diagnose prostate cancer from urine

Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on PSA, a cancer factor in blood.

21 Jan 2021

Mediterranean diet has the potential to effect progression of prostate cancer

In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.

7 Jan 2021

Genetic risk score can be used to determine risk of developing prostate cancer

Some racial and ethnic groups suffer relatively more often, and fare worse, from common ailments compared to others. Prostate cancer is one disease where such health disparities occur: risk for the disease is about 75 percent higher, and prostate cancer is more than twice as deadly, in Blacks compared to whites.

4 Jan 2021

First PSMA-targeted PET imaging drug approved for men with prostate cancer

Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.

1 Dec 2020

Negative biopsies during active surveillance for prostate cancer are associated with long-term outcomes

Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"--either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®.

18 Nov 2020

Active surveillance is a safe and viable option for men with low-risk prostate cancer

Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in The Journal of Urology®, an Official Journal of the American Urological Association.

9 Nov 2020

Study shows active surveillance to be safe for African American men with low-risk prostate cancer

Previous studies have shown that African American men are 2.4 times as likely to die from prostate cancer compared to non-Hispanic white men.

3 Nov 2020

New staging system can inform treatment decisions for non-metastatic prostate cancer

Doctors and biostatisticians at the University of Michigan Rogel Cancer Center have led the development and validation of a staging system to better predict outcomes and inform treatment decisions for men diagnosed with non-metastatic prostate cancer.

23 Oct 2020

PARP inhibitor can successfully treat a subset of advanced prostate cancer patients

Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib, resulting in recent FDA approval.

15 Aug 2020

Developing a blood test for prostate cancer

Professor Pockley among researchers from the John van Geest Cancer Research Centre have recently developed a blood test for the detection of prostate cancer.

13 Aug 2020

PSMA PET/CT has high impact in the detection, management of recurrent prostate cancer

New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients.

13 Jul 2020

Benefits of PSA screening for prostate cancer may outweigh potential harms

The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, according to a study published today in the New England Journal of Medicine.

22 Jun 2020

Studies show prognostic value for circulating tumor cells in advanced prostate and breast cancer

Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology suggest that circulating tumor cell counts may be useful in determining long-term prognosis and guiding treatment selection in patients with metastatic castrate sensitive prostate cancer.

10 Jun 2020

Prostate Specific Antigen News and Research

New urine test could avoid unnecessary prostate cancer biopsies

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer

New technique can rapidly diagnose prostate cancer from urine

Mediterranean diet has the potential to effect progression of prostate cancer

Genetic risk score can be used to determine risk of developing prostate cancer

First PSMA-targeted PET imaging drug approved for men with prostate cancer

Negative biopsies during active surveillance for prostate cancer are associated with long-term outcomes

Active surveillance is a safe and viable option for men with low-risk prostate cancer

Study shows active surveillance to be safe for African American men with low-risk prostate cancer

New staging system can inform treatment decisions for non-metastatic prostate cancer

PARP inhibitor can successfully treat a subset of advanced prostate cancer patients

Developing a blood test for prostate cancer

PSMA PET/CT has high impact in the detection, management of recurrent prostate cancer

Benefits of PSA screening for prostate cancer may outweigh potential harms

Studies show prognostic value for circulating tumor cells in advanced prostate and breast cancer

Health disparities negatively impact various groups of people

Blood test may predict a patient’s response to prostate cancer treatment

Genetic screening could be effective at detecting undiagnosed cases of prostate cancer

Study: New biopsy methods can help improve benefit-harm ratio of PSA screening

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News